We are live on ! Find out more
IRD

Opus Genetics

43 hedge funds and large institutions have $16.5M invested in Opus Genetics in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

12% more capital invested

Capital invested by funds: $14.7M → $16.5M (+$1.8M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3.55% less ownership

Funds ownership: 32.89%29.34% (-3.6%)

7% less funds holding

Funds holding: 4643 (-3)

22% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 9

Holders
43
Holders Change
-3
Holders Change %
-6.52%
% of All Funds
0.57%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
7
Increased
10
Reduced
8
Closed
9
Calls
$20K
Puts
Net Calls
+$20K
Net Calls Change
+$6K
Name Holding Trade Value Shares
Change
Change in
Stake
EB
51
Eastern Bank
Massachusetts
-$982 -1,000 Closed
JP Morgan Chase
52
JP Morgan Chase
New York
-$57 -58 Closed

IRD Hedge Fund Activity: Q2 2025 in Review

43 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q2 2025, worth a combined $16.5M — up 12% from $14.7M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of IRD and 7 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 10 added.

The largest buyer was BIOS Capital Management, adding an estimated $2.49M. The largest seller was AWM Investment Company, exiting entirely with an estimated $515K sold.

  • 43 institutional investors held Opus Genetics (IRD) as of Q2 2025, down from 46 in Q1 2025.
  • Funds reported $16.5M of Opus Genetics stock for Q2 2025, up 12% quarter-over-quarter.
  • 7 funds opened new Opus Genetics positions in Q2 2025 and 9 closed out, a net change of -2 holders.
  • The largest Opus Genetics buyer in Q2 2025 was BIOS Capital Management, an estimated $2.49M added.
  • The largest Opus Genetics seller in Q2 2025 was AWM Investment Company, an estimated $515K sold.

Based on aggregated 13F filings for Q2 2025.